A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 04 Nov 2016 This trial was completed in Czech Republic, according to Eudra record.
- 01 Oct 2016 This trial was completed in Spain according to European Clinical Trials Database record.
- 01 Aug 2016 Planned End Date changed from 1 Jul 2019 to 1 Sep 2017.